Americans spend billions of dollars on products to address specific hair and scalp concerns each year—whether that be color, condition, or appearance.
Completion of Phase I of ASHP’s Standardize 4 Safety initiative is fast approaching.
Community pharmacists are caught in the middle of a battle between patients and their health insurers over how the federal government defines medical foods and how patients are paying for them.
When Express Scripts and CVS Health announced their 2017 formularies on August 1, a common theme emerged among the healthcare giants: several blockbuster drugs will be removed from both companies’ formularies and lower-cost options such as biosimilars are being embraced.
FDA approved Onzetra Xsail (Avanir Pharmaceuticals Inc.)— a fast-acting, low-dose sumatriptan dry powder formulation for the acute treatment of migraine with or without aura in adults.
According to FDA and other sources, tobacco use is the single largest preventable cause of disease and death in the United States.
Occasionally, it can be interesting to learn what pharmacists and other insiders foresee as the industry’s future
FDA’s method for naming biosimilars and interchangeable biologics came under fire long before the first biosimilar, Zarxio, was approved last spring.